Making AI Headlines · Page 3
OpenAI Adds Orchestra Bio to Its Life Sciences Work
· New York time
OpenAI is acquiring Orchestra Bio and says the startup's team and technology will support Rosalind, its life sciences research model, and the related Rosalind Workbench. The workbench aims to help researchers plan experiments and analyze results. The acquisition places more of OpenAI's effort inside specialized research workflows, where useful assistance requires more than producing a convincing paragraph. Planning an experiment, organizing research operations and interpreting results involve different demands from drafting a routine office email. Biology remains inconveniently unwilling to accept a polished presentation as experimental evidence. OpenAI presents the deal as a way to accelerate life sciences research and drug development. Those are goals, not demonstrated treatment outcomes from the acquisition. The immediate development is the addition of people and technology to a research platform, with its ultimate scientific value depending on what researchers can accomplish with it. For biopharma teams, the attraction is support for work that combines complex information with complicated operations. The office fantasy is that an assistant will organize everything before the next meeting. The laboratory version adds a further requirement: the experiment must still work outside the meeting. Rosalind may get a stronger workbench, but the bench does not get to vote on whether a hypothesis survives.
Read this story in the full newspaper →Satire. Not factual reporting. Read the original reporting from the linked publishers.